Semaglutide: Independent Evidence on Weight Loss, Risks & Money

Table of contents

• Evidence summary
• What semaglutide is
• How it works
• What it is prescribed for
• What works and what does not
• Benefits by claim
• Risks and all side effects
• All interactions
• Who should avoid semaglutide
• Dosage and how to take it (label doses)
• Follow the money: who makes it and who funded the evidence
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

Independent evidence and credibility scorecard

Independence tiers: 1 = regulator or government body; 2 = academic or Cochrane team with no declared commercial funding for the work; 3 = independent authors analysing mostly manufacturer-run trials, or minor declared industry ties; 4 = manufacturer-funded or manufacturer-authored. Credibility runs from A (highest) to D.

The sources are spread across the US, the EU, the UK, Canada, China and Denmark, but US bodies make up five of the twelve. The randomised evidence on benefit comes almost entirely from one company. The strongest signal is where sources with opposing interests agree. NICE, Medicare's negotiators and ICER all have a financial reason to doubt the drug, yet they accept that it produces large weight loss. Harm signals mostly come from independent researchers, and the EU regulator confirmed one of them (NAION).

What semaglutide is

Semaglutide is a man-made version of GLP-1 (glucagon-like peptide-1), a gut hormone, altered so that it lasts about a week in the body. It is sold under three main brand names, all made by Novo Nordisk:

• Ozempic: a weekly injection for type 2 diabetes. In the US it is also licensed to cut cardiovascular risk in people with diabetes and heart disease, and to slow kidney decline in people with diabetes and chronic kidney disease (Ozempic label).
• Rybelsus: a daily tablet for type 2 diabetes. The US label now also lists a separate "Ozempic tablet", and states that the two are not interchangeable mg for mg (Rybelsus label).
• Wegovy: a weekly injection, and since late 2025 in the US a daily 25 mg tablet. It is licensed for weight reduction in adults and children aged 12 and over, for cutting cardiovascular events in adults with heart disease and overweight, and for a fatty-liver condition (MASH) with liver scarring (Wegovy label). Novo Nordisk says the FDA approved the tablet on 22 December 2025 (Novo Nordisk).

Semaglutide is prescription-only everywhere we checked. In the UK, Ozempic is licensed for diabetes, not weight loss, although it is used off-label for that purpose (MHRA). Copies made by US compounding pharmacies are not FDA-approved (FDA). Novo Nordisk says the compound patent has now expired in "certain" markets outside the US (Novo Nordisk, February 2026).

How it works

Semaglutide acts on the same receptor as natural GLP-1. According to the EMA, it raises the amount of insulin the pancreas releases in response to food. It also increases fullness and reduces food intake, hunger and cravings (EMA). The US label adds three points. It lowers glucagon in a glucose-dependent way. It slows stomach emptying. And it lowers body weight "with greater fat mass loss than lean mass loss", probably mostly by reducing appetite (Wegovy label).

Proven in humans: lower blood sugar, lower calorie intake, slower stomach emptying and weight loss. Not fully established: how much of the heart and kidney benefit comes from weight loss and how much from direct effects. Also unknown is whether the thyroid C-cell tumours seen in rodents matter for people. The label says human relevance "has not been determined" (Wegovy label).

Because it works by being "glucose-dependent", semaglutide on its own rarely causes dangerous lows. The risk rises when it is combined with insulin or sulfonylureas (see interactions). The slower stomach emptying explains much of the nausea and fullness. It is also why anaesthetists want to know about it before surgery.

What it is prescribed for

Type 2 diabetes. Ozempic and Rybelsus are licensed with diet and exercise to improve blood-sugar control. Ozempic is also licensed for cardiovascular and kidney protection in specific high-risk groups (Ozempic label).

Obesity and overweight. In the US, Wegovy is licensed for adults with obesity, or with overweight plus at least one weight-related condition, and for children aged 12 and over with obesity (Wegovy label). On the NHS in England, NICE restricts it to adults treated in a specialist weight-management service with at least one weight-related condition. They also need a BMI of at least 35, or 30 to 34.9 if they meet referral criteria, with lower thresholds for some ethnic groups. NHS use is capped at two years, and NICE advises considering stopping if less than 5% of weight has been lost after six months (NICE TA875).

Where independent guidelines place it. In December 2025 the WHO issued its first obesity-drug guideline. It says GLP-1 therapies "may be used" long term by adults, excluding pregnant women. The recommendation is conditional because of limited data on long-term efficacy and safety, maintenance and stopping, as well as cost and health-system readiness (WHO). The NICE committee limited NHS use to two years because of restricted time in specialist services and a lack of evidence for longer use. It also noted that longer treatment made semaglutide less cost-effective in the model, because the benefits plateaued (NICE committee discussion).

What works and what does not

Benefits by claim

Weight loss

STEP 1 enrolled 1,961 adults without diabetes. All had a BMI of 30 or more, or 27 or more with a weight-related condition. They were randomly assigned to weekly semaglutide 2.4 mg or placebo, both alongside lifestyle support. After 68 weeks, average weight change was −14.9% on semaglutide and −2.4% on placebo. That is a difference of 12.4 percentage points (95% CI 11.5 to 13.4), or 12.7 kg. Weight loss of at least 10% was reached by 69.1% of people on semaglutide and 12.0% on placebo. The trial was "Funded by Novo Nordisk" (Wilding 2021).

In plain terms, someone weighing 100 kg would lose about 15 kg on average, against about 2 to 3 kg with lifestyle support alone. That is an average, and responses vary widely: about one person in seven on semaglutide lost less than 5%.

Independent bodies looked at the same programme and reached similar conclusions. ICER's independent panel judged that the drug gives a net health benefit when added to lifestyle change (ICER). NICE accepted that people lose more weight with semaglutide plus supervised support than with support alone (NICE). The US label now allows a dose of up to 7.2 mg weekly for adults who tolerate 2.4 mg and need more weight loss (Wegovy label). We did not review the trial behind that higher dose.

What happens when you stop

In the STEP 1 extension, treatment and lifestyle support both ended at week 68, and 327 people were followed for another year. Those on semaglutide had lost 17.3% on average. By week 120 they had regained 11.6 percentage points, leaving a net loss of 5.6%. Blood pressure, cholesterol and blood-sugar improvements "reverted towards baseline" for most measures. The authors, several of whom report Novo Nordisk fees or grants, concluded that "ongoing treatment is required" (Wilding 2022).

STEP 4 tested the question directly. In that trial, 803 people who had lost 10.6% over a 20-week run-in were randomised either to continue or to switch to placebo. Over the next 48 weeks, those who continued lost a further 7.9%, while those switched to placebo gained 6.9%. Novo Nordisk funded the trial, its representatives took part in design and analysis, and agency medical writers helped prepare the paper (Rubino 2021). Both the maker and independent reviewers draw the same conclusion: for most people, semaglutide is a long-term treatment. NICE itself said a two-year maximum was "not ideal" for a chronic condition, and the WHO flagged "maintenance and discontinuation" as an evidence gap (WHO).

Heart attacks and strokes

Without diabetes (SELECT). SELECT enrolled 17,604 people aged 45 or over with existing cardiovascular disease and a BMI of 27 or more. Cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over about 40 months (HR 0.80, 95% CI 0.72 to 0.90). Put simply, about 15 events were prevented per 1,000 people treated for just over three years. Adverse events led 16.6% of the semaglutide group to stop permanently, against 8.2% on placebo. The trial was funded by Novo Nordisk (Lincoff 2023). It does not show heart benefit for people with obesity but no heart disease.

With type 2 diabetes. SUSTAIN-6 was designed mainly as a safety study, to rule out harm. It found 6.6% vs 8.9% major cardiovascular events (HR 0.74, 0.58 to 0.95), but also more serious diabetic eye complications (HR 1.76, 1.11 to 2.78) (Marso 2016). PIONEER 6, which tested the tablet, met its safety goal but did not show a significant reduction (HR 0.79, 0.57 to 1.11) (Husain 2019). Both trials were funded by Novo Nordisk.

Kidney disease in type 2 diabetes

FLOW randomised 3,533 people with type 2 diabetes and chronic kidney disease to semaglutide 1 mg or placebo. Major kidney events (kidney failure, a 50% fall in kidney function, or kidney or cardiovascular death) were 24% lower (HR 0.76, 0.66 to 0.88). Death from any cause was 20% lower (HR 0.80, 0.67 to 0.95). The trial stopped early at a planned interim analysis. It was funded by Novo Nordisk (Perkovic 2024). Trials stopped early for benefit can overstate effects, so we rate this as moderate.

Mood and suicidal thoughts

This is not a benefit claim, but it is one of the most searched questions about semaglutide. The answer from three independent directions is reassuring. In April 2024 the EMA safety committee concluded that the evidence "does not support a causal association" (EMA). In 2026, the FDA published a meta-analysis of 91 placebo-controlled trials (60,338 people on a GLP-1 drug and 47,572 on placebo). It showed no increased risk of suicidal thoughts or behaviour, anxiety, depression or psychosis. The FDA then asked for the warning to be removed from Wegovy's label (FDA). An NIH-funded study of 240,618 people with overweight or obesity found semaglutide was linked to fewer recurrent suicidal thoughts than other weight-loss drugs (HR 0.44, 0.32 to 0.60) (Wang 2024). The FDA's earlier 2024 statement had noted that a small risk "cannot definitively" be ruled out (FDA 2024). Anyone with new or worsening low mood should still tell their clinician.

Risks and all side effects

Common side effects

The Wegovy label lists side effects reported by at least 2% of adults on 2.4 mg and more often than on placebo (Wegovy label, Table 3):

• Nausea 44% (placebo 16%); diarrhoea 30% (16%); vomiting 24% (6%); constipation 24% (11%); abdominal pain 20% (10%)
• Headache 14% (10%); fatigue 11% (5%); dizziness 8% (4%)
• Indigestion 9%; bloating 7%; belching 7%; wind 6%; gastroenteritis 6%; reflux 5%; gastritis 4%
• Low blood sugar in people with type 2 diabetes 6% (2%)
• Hair loss 3% (1%); altered skin sensation (dysaesthesia) 2% (1%)

In STEP 1, these stomach and bowel effects were mostly mild to moderate and eased over time. Still, 4.5% of people stopped semaglutide because of them, against 0.8% on placebo (STEP 1). The label tells prescribers to increase the dose slowly to limit them, and says the drug is not recommended in severe gastroparesis (Wegovy label).

Muscle and lean mass

Any large weight loss includes some lean tissue. In a 140-person scanning sub-study of STEP 1, semaglutide reduced total fat mass by 19.3% and lean mass by 9.7%. Because fat fell faster, lean mass made up a larger share of the body afterwards (STEP 1 body-composition abstract). This was an exploratory analysis of a Novo Nordisk-funded trial, published as a conference abstract. It did not measure strength, falls or physical function. "Lean mass" on these scans also includes water and organs, not just muscle. We found no independent long-term trial of muscle outcomes, so this question remains open, especially for older adults.

Fake, compounded and "research" products

Global demand and a three-year shortage created a large unlicensed market. Semaglutide injections were on the FDA shortage list from March 2022 (Wegovy) and August 2022 (Ozempic), until the FDA declared the shortage over on 21 February 2025 (FDA declaratory order).

• Fakes. The UK's MHRA seized 369 potentially fake Ozempic pens in 2023. A small number of people were hospitalised, with "hypoglycaemic shock and coma" among the effects reported (MHRA). A 2024 WHO alert covered falsified Ozempic batches found in Brazil, the UK and the US, some of them "in the regulated supply chain" (WHO).
• Compounded copies (US). The FDA reports dosing errors with compounded products, sometimes needing hospital care. It also reports salt forms of semaglutide (sodium, acetate) for which it knows of no lawful basis, and labels naming pharmacies that do not exist. By 31 May 2026 it had received 990 adverse-event reports for compounded semaglutide. It warns that the true number is likely higher, because most pharmacies are not required to report (FDA).

All interactions

• Insulin and sulfonylureas (such as gliclazide and glimepiride): higher risk of low blood sugar, including severe episodes. The label advises considering a lower dose of these drugs (Wegovy label).
• Other medicines taken by mouth: slower stomach emptying may change how they are absorbed. In a study with the semaglutide tablet, levothyroxine (thyroid hormone) levels rose by 33%. The label advises extra monitoring for drugs with a narrow safety margin or that need monitoring. The injection at 1 mg did not affect absorption in pharmacology studies (Wegovy label).
• Tablets (Rybelsus, Ozempic tablets, Wegovy tablets): take them on an empty stomach with up to 4 ounces (about 120 ml) of water. Then wait at least 30 minutes before eating, drinking or taking other oral medicines (Rybelsus label).
• Anaesthesia and sedation: there have been reports of inhaling stomach contents. Tell the surgical team you take semaglutide before any planned procedure (Wegovy label).
• Other GLP-1 medicines: do not combine semaglutide with another GLP-1 drug, such as liraglutide, tirzepatide or a compounded GLP-1. This is standard prescribing practice. We did not find a specific label statement to cite, so check with a pharmacist.

Who should avoid semaglutide

Contraindications

• A personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia type 2 (MEN 2)
• A previous serious allergic reaction to semaglutide or any ingredient (Wegovy label)

Use with care

• Severe gastroparesis: not recommended
• Diabetic retinopathy: needs monitoring
• Gallstones, or a history of pancreatitis: discuss with the prescriber; stop if pancreatitis is suspected
• Risk of dehydration or kidney problems: monitor kidney function if vomiting or diarrhoea occurs (Wegovy label)

Pregnancy, breastfeeding and fertility

The US label says Wegovy "may cause fetal harm". For weight or heart-risk use, it should be stopped once pregnancy is recognised, and at least two months before a planned pregnancy because the drug lasts a long time in the body. Breastfeeding is not recommended while taking Wegovy tablets (Wegovy label). The WHO guideline excludes pregnant women from its recommendation (WHO).

Children and adolescents

In the US, Wegovy injection is licensed from age 12 for obesity. Gallstones were more common in adolescents than adults in trials (Wegovy label). The WHO recommendation covers adults only.

Older adults

The lean-mass question matters most here, and there is no long-term independent evidence on strength or falls (see muscle and lean mass).

Dosage and how to take it (label doses)

These are the doses stated on official US labels, shown for reference only. Doses are set and adjusted by the prescriber.

Wegovy injection (weight, heart risk, MASH)

Label schedule: 0.25 mg once weekly for weeks 1–4, then 0.5 mg (weeks 5–8), 1 mg (weeks 9–12) and 1.7 mg (weeks 13–16). The maintenance dose for adult weight loss is 1.7 mg or 2.4 mg (2.4 mg recommended). The label allows up to 7.2 mg weekly for adults who tolerate 2.4 mg for at least four weeks and need more weight loss. If two or more weekly doses in a row are missed, the label says to restart at a lower dose (Wegovy label).

Wegovy tablets

Label schedule: 1.5 mg once daily for 30 days, increased every 30 days to a 25 mg daily maintenance dose (Wegovy label).

Ozempic injection (type 2 diabetes)

Label schedule: 0.25 mg once weekly for four weeks, then 0.5 mg. This can be increased to 1 mg and then 2 mg, each after at least four weeks, if more blood-sugar control is needed. For kidney protection, the label dose is 1 mg. A missed dose can be taken within five days (Ozempic label).

Rybelsus tablets (type 2 diabetes)

Label schedule: 3 mg daily for 30 days (a starter dose "not effective for glycemic control"), then 7 mg, with the option of 14 mg (Rybelsus label). In 2024 the EMA's safety committee agreed a letter to European doctors explaining the differences between the existing and newly proposed tablet formulations (EMA).

How long to take it, and stopping

No label or guideline we reviewed sets a natural end point. NHS funding is capped at two years (NICE), while the trials show weight regain after stopping (STEP 1 extension). Decisions about stopping belong with the prescriber.

Product quality

The FDA's advice is to get a prescription and fill it at a state-licensed pharmacy. Red flags include prices that seem too good to be true, no requirement for a prescription, spelling errors or wrong addresses on labels, and medicine that looks different from before (FDA). Never share a pen, even with a new needle (Wegovy label).

Follow the money: who makes it and who funded the evidence

Who makes it, and who owns the maker

Semaglutide is made by Novo Nordisk A/S, headquartered in Bagsværd, Denmark. Its B shares are listed in Copenhagen and its ADRs in New York (Novo Nordisk). Control sits with the Novo Nordisk Foundation, a Danish foundation. Through its wholly owned subsidiary Novo Holdings A/S, it held about 28.1% of the share capital and about 77.3% of the votes at the end of 2025. Its articles of association oblige it to keep a controlling interest (Novo Nordisk Foundation). The foundation also runs grant programmes, so part of the profit from semaglutide flows back into research funding.

How much money semaglutide makes

In 2025 Novo Nordisk's total sales were DKK 309.1 billion, with operating profit of DKK 127.7 billion (Novo Nordisk, 3 February 2026). Ozempic alone brought in DKK 127.1 billion. Rybelsus brought in DKK 22.1 billion. Obesity-care products, led by Wegovy, brought in DKK 82.3 billion (Annual Report 2025). In mid-2025 the company cut its outlook, citing "persistent use of compounded GLP-1s" and competition (Novo Nordisk, August 2025). For 2026 it expects adjusted sales to fall by 5–13% at constant exchange rates. It blames lower US prices, a "Most Favoured Nations" agreement with the US administration, patent expiry in some markets outside the US, and competition (Novo Nordisk).

US pricing

• The 2024 US list price for a 30-day supply of Ozempic, Rybelsus or Wegovy was $959. The negotiated price from 2027 is $274, a 71% discount. In 2024, Medicare Part D spent about $15.2 billion on these products for 2.28 million people (CMS).
• In November 2025 Novo Nordisk cut its US self-pay price for Wegovy and Ozempic from $499 to $349 a month (Ozempic 2 mg stayed at $499). It also ran a $199-a-month introductory offer on the two lowest doses for new self-pay patients, which ended on 31 March 2026 (Novo Nordisk US).
• In February 2026 it announced that from 1 January 2027 the US list price for all three brands will fall to $675 a month. The company describes this as roughly a 50% cut for Wegovy and 35% for Ozempic (Novo Nordisk).
• ICER estimated the US net price of injectable semaglutide at $6,829 a year. It judged the drug cost-effective, but warned that the number of people eligible would strain the US health system (ICER).

Who funded the evidence

Every pivotal trial in this article was funded by Novo Nordisk: STEP 1, the STEP 1 extension, STEP 4, SELECT, SUSTAIN-6, PIONEER 6 and FLOW. In STEP 4, the company's representatives were involved in design, data analysis and manuscript approval, and medical writers from a communications agency helped prepare the paper (Rubino 2021). Several STEP 1 extension authors report Novo Nordisk grants, fees or advisory roles, alongside ties to its competitors (Wilding 2022). That does not make the results wrong. These were large, registered, double-blind trials, and regulators audit them. But no fully independent randomised trial confirms the outcome benefits.

The independent work is concentrated on harms and value. It includes a Canadian university study on bowel and pancreatic events, a charity-funded US eye study, an NIH-funded study on suicidal thoughts, a Chinese publicly funded meta-analysis on gallbladder disease, and regulator reviews. The two main regulators also take money from industry. EMA gets about 91.5% of its budget from company fees (EMA), and the FDA collected $1.458 billion in prescription-drug user fees in FY 2025 (FDA). Even so, the EMA added a new NAION warning against the seller's interest.

Documented integrity and supply events

• Shortage, 2022–2025: the FDA listed semaglutide injections as in shortage from 2022. It declared the shortage resolved on 21 February 2025, based on production and inventory data supplied by Novo Nordisk (FDA). During shortages, US law gives compounders more room to copy a drug, which helped fuel the compounded market.
• Counterfeits: MHRA seizures in 2023 and a WHO global alert in 2024 (MHRA; WHO).
• Label change in the seller's favour: in 2026 the FDA asked for the suicidality warning to be removed. This followed the FDA's own meta-analysis, not a company study (FDA).

Related research

For wider, evidence-graded context, see these Pure City Research guides:

• Diabetes and cardiovascular disease
• Diabetes prevention guide
• Diabetes supplements: the evidence
• Berberine and blood sugar
• MASLD and MASH (fatty liver disease)
• Gallstones
• Acute cholecystitis
• Acute pancreatitis
• Heart failure with preserved ejection fraction
• Chronic kidney disease and the heart
• Obstructive sleep apnoea
• Stress, depression and cardiovascular disease

Frequently asked questions

Sources and funding notes

What we could not verify: We could not open the US Senate HELP Committee's 2024 report on Novo Nordisk pricing, because the Senate website blocked automated access, so we have not cited its international price comparisons. We did not open the full SELECT, SUSTAIN-6, PIONEER 6 and FLOW papers to check author conflicts, and relied on their abstracts' funding lines. The STEP 1 body-composition data are a conference abstract, and we found no peer-reviewed full paper to check. We did not review the larger independent NAION studies the EMA cites, or the trial behind the 7.2 mg Wegovy dose. We could not confirm Wegovy's separate 2025 sales figure, only the total for obesity care. We could not confirm the exact markets where the semaglutide patent has expired. We could not confirm US self-pay prices as of October 2026, after the $199 introductory offer ended. We could not verify Novo Nordisk Foundation grant totals, or whether any foundation-funded researchers worked on the studies cited.

1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM 2021: pivotal obesity trial; funded by Novo Nordisk.
2. Wilding JPH et al. Weight regain after withdrawal of semaglutide: STEP 1 extension. Diabetes Obes Metab 2022: off-treatment follow-up; funded by Novo Nordisk; authors report industry ties.
3. Rubino D et al. Continued vs withdrawn semaglutide (STEP 4). JAMA 2021: withdrawal trial; funded by Novo Nordisk, which co-designed and analysed it.
4. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM 2023: outcome trial; funded by Novo Nordisk.
5. Marso SP et al. Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6). NEJM 2016: safety and outcome trial; funded by Novo Nordisk.
6. Husain M et al. Oral semaglutide and cardiovascular outcomes (PIONEER 6). NEJM 2019: safety trial; funded by Novo Nordisk.
7. Perkovic V et al. Semaglutide and chronic kidney disease in type 2 diabetes (FLOW). NEJM 2024: kidney outcome trial; funded by Novo Nordisk.
8. Impact of semaglutide on body composition: exploratory analysis of STEP 1. J Endocr Soc 2021 (abstract): DXA sub-study of a Novo Nordisk-funded trial.
9. He L et al. GLP-1 receptor agonists and gallbladder and biliary diseases: meta-analysis. JAMA Intern Med 2022: Peking Union Medical College Hospital; National Natural Science Foundation of China and other public grants; no conflicts reported.
10. Sodhi M et al. Gastrointestinal adverse events with GLP-1 agonists for weight loss. JAMA 2023: University of British Columbia internal funds; no conflicts reported.
11. Hathaway JT et al. Risk of NAION in patients prescribed semaglutide. JAMA Ophthalmol 2024: part-funded by Research to Prevent Blindness; no conflicts reported.
12. Wang W et al. Semaglutide and risk of suicidal ideation in a real-world cohort. Nat Med 2024: NIH grants (NIA, NIAAA, NCI).
13. EMA. PRAC concludes NAION is a very rare side effect of semaglutide medicines (6 June 2025): EU regulator.
14. EMA. PRAC meeting highlights, 8–11 April 2024 (GLP-1 and suicidal thoughts; Rybelsus formulations): EU regulator.
15. EMA. Funding: EMA budget sources.
16. FDA. Drug Safety Communication: removal of suicidal behaviour and ideation warning from GLP-1 RA labels (13 January 2026): US regulator.
17. FDA. Update on ongoing evaluation of suicidal thoughts with GLP-1 RAs (January 2024): US regulator.
18. FDA. Concerns with unapproved GLP-1 drugs used for weight loss (current as of 1 October 2026): US regulator.
19. FDA. Declaratory order: resolution of shortages of semaglutide injection products (21 February 2025): US regulator.
20. FDA. PDUFA financial report to Congress, FY 2025: user-fee funding of drug review.
21. Wegovy (semaglutide) injection and tablets, US prescribing information (DailyMed): FDA-approved label; written by Novo Nordisk, approved by FDA.
22. Ozempic (semaglutide) injection, US prescribing information (DailyMed): FDA-approved label.
23. Rybelsus and Ozempic tablets, US prescribing information (DailyMed): FDA-approved label.
24. NICE TA875. Semaglutide for managing overweight and obesity (2023); committee discussion: UK health-technology body; accountable to DHSC.
25. MHRA. MHRA warns of unsafe fake weight loss pens (26 October 2023): UK regulator.
26. WHO. Medical Product Alert N°2/2024: falsified Ozempic (19 June 2024): WHO.
27. WHO. Global guideline on GLP-1 medicines in treating obesity (1 December 2025): WHO; funding model.
28. ICER. Final evidence report on treatments for obesity (16 December 2025): US non-profit; funded mainly by foundations.
29. CMS. Negotiated prices for initial price applicability year 2027 (fact sheet): US government payer.
30. Novo Nordisk. Financial report for 2025 (3 February 2026): company.
31. Novo Nordisk Annual Report 2025: financial performance: company.
32. Novo Nordisk. Financial report for the first six months of 2025 (6 August 2025): company.
33. Novo Nordisk. US list price reduction for Wegovy, Ozempic and Rybelsus (24 February 2026): company.
34. Novo Nordisk Inc. Introductory self-pay offer for Wegovy and Ozempic (17 November 2025): company.
35. Novo Nordisk Foundation. Ownership: controlling shareholder.

Educational research reviewed 7 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.